CYP19A1 and breast cancer: Using droplet digital PCR (ddPCR), Clatot et al. observed ESR1 D538, Y537S/N/C mutations in 30.6% of plasma samples derived from patients with metastatic BC which had progressed after first-line aromatase inhibitor therapy [46].